---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-094609"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2024-08-29T23:59:59+00:00"
generated_at: "2026-05-31T07:02:25.567038+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma gets FDA Orphan Drug Designation for NXP800 in ARID1a-deficient ovarian cancers

## Summary
- FDA granted Orphan Drug Designation for NXP800 for treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.
- CEO Ron Bentsur noted prevalence exceeds 200,000 threshold; designation for a disease subset is uncommon.
- Ongoing Phase 1b trial in platinum-resistant ARID1a-mutated ovarian cancer; data update expected fall 2024.
- Nuvectis Pharma (NVCT) stock trades on Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001104659-24-094609
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2024-08-29T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465924094609/0001104659-24-094609-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465924094609/tm2422951d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-094609
- JSON: https://secwatch.observer/filing/0001104659-24-094609.json
- Plain text: https://secwatch.observer/filing/0001104659-24-094609.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.